이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 골수 증식성 신생물(MPN)에서 Iadademstat 유무에 관계없이 ASTX727에 대한 무작위 연구

2026년 10월 24일 업데이트: National Cancer Institute (NCI)

가속/폭발 단계 필라델피아 염색체 음성 골수 증식성 신생물(MPN)에 대한 ASTX727 +/- Iadademstat의 무작위 2상 시험

This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To compare the acute leukemia response-complete (ALR-C) rate of iadademstat + ASTX727 (35 mg decitabine + 100 mg cedazuridine) and ASTX727 (35 mg decitabine + 100 mg cedazuridine) monotherapy within 4 cycles of therapy in patients with accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP) previously untreated with deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi).

SECONDARY OBJECTIVE:

I. To compare event-free survival (EFS), overall survival (OS), and percentage of patients going onto allogeneic hematopoietic stem cell transplant (allo-HCT) of iadademstat + ASTX727 (35 mg decitabine + 100 mg cedazuridine) and ASTX727 (35 mg decitabine + 100 mg cedazuridine) monotherapy in patients with MPN-AP/BP previously untreated with DNMTi.

EXPLORATORY OBJECTIVES:

I. To compare iadademstat target engagement between patients treated with iadademstat + ASTX727 (35 mg decitabine + 100 mg cedazuridine) and ASTX727 (35 mg decitabine + 100 mg cedazuridine) monotherapy by evaluating transcriptional changes in proliferative pathways implicated in MPN-AP/BP development and/or progression.

II. To elucidate the common molecular pathways of resistance/progression in patients with MPN-AP/BP receiving DNMTi-based therapy.

III. To measure response using the European LeukemiaNet 2022 Acute Myeloid Leukemia (AML) criteria (Döhner et al., 2022) and compare with the 2012 MPN-BP criteria that is being utilized for primary objective assessment.

OUTLINE: This is a dose escalation study of ASTX727 and iadademstat followed by a randomized study. Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ASTX727 orally (PO) once daily (QD) on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.

ARM II: Patients receive ASTX727 PO QD on days 1-5 and iadademstat PO QD on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.

After completion of study treatment, patients who stop the study for reasons other than disease progression are followed up every 3 months. Patients who stop the study due to disease progression, are followed up every 6 months.

연구 유형

중재적

등록 (추정된)

78

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Irvine, California, 미국, 92612
        • 모병
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • 수석 연구원:
          • Kiran Naqvi
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-827-8839
          • 이메일: ucstudy@uci.edu
      • Orange, California, 미국, 92868
        • 모병
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • 수석 연구원:
          • Kiran Naqvi
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-827-8839
          • 이메일: ucstudy@uci.edu
      • Palo Alto, California, 미국, 94304
        • 모병
        • Stanford Cancer Institute Palo Alto
        • 수석 연구원:
          • Gabriel N. Mannis
        • 연락하다:
      • Sacramento, California, 미국, 95817
        • 모병
        • University of California Davis Comprehensive Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 916-734-3089
        • 수석 연구원:
          • Francisco A. Socola
    • Florida
      • Coral Gables, Florida, 미국, 33146
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Coral Springs, Florida, 미국, 33065
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Coral Springs
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Deerfield Beach, Florida, 미국, 33442
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Doral, Florida, 미국, 33166
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Doral
        • 연락하다:
        • 수석 연구원:
          • Terrence J. Bradley
      • Hollywood, Florida, 미국, 33021
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Hollywood
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Miami, Florida, 미국, 33176
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Kendall
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • North Miami, Florida, 미국, 33181
        • 모병
        • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
        • 연락하다:
        • 수석 연구원:
          • Terrence J. Bradley
      • Plantation, Florida, 미국, 33324
        • 모병
        • UM Sylvester Comprehensive Cancer Center at Plantation
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Terrence J. Bradley
      • Tampa, Florida, 미국, 33612
        • 모병
        • Moffitt Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Andrew T. Kuykendall
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Anand A. Patel
      • New Lenox, Illinois, 미국, 60451
        • 모병
        • UC Comprehensive Cancer Center at Silver Cross
        • 연락하다:
        • 수석 연구원:
          • Anand A. Patel
      • Orland Park, Illinois, 미국, 60462
        • 모병
        • University of Chicago Medicine-Orland Park
        • 연락하다:
        • 수석 연구원:
          • Anand A. Patel
    • Indiana
      • Crown Point, Indiana, 미국, 46307
        • 모병
        • UChicago Medicine Northwest Indiana
        • 연락하다:
        • 수석 연구원:
          • Anand A. Patel
    • Kansas
      • Fairway, Kansas, 미국, 66205
        • 모병
        • University of Kansas Clinical Research Center
        • 연락하다:
        • 수석 연구원:
          • Abdulraheem M. Yacoub
      • Kansas City, Kansas, 미국, 66160
        • 모병
        • University of Kansas Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Abdulraheem M. Yacoub
      • Overland Park, Kansas, 미국, 66211
        • 모병
        • University of Kansas Hospital-Indian Creek Campus
        • 연락하다:
        • 수석 연구원:
          • Abdulraheem M. Yacoub
      • Westwood, Kansas, 미국, 66205
        • 모병
        • University of Kansas Hospital-Westwood Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Abdulraheem M. Yacoub
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • NYP/Weill Cornell Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 212-746-1848
        • 수석 연구원:
          • Ghaith Abu Zeinah
    • North Carolina
      • Charlotte, North Carolina, 미국, 28203
        • 모병
        • Carolinas Medical Center/Levine Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-804-9376
        • 수석 연구원:
          • Brittany K. Ragon
      • Concord, North Carolina, 미국, 28025
        • 모병
        • Atrium Health Cabarrus/LCI-Concord
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-804-9376
        • 수석 연구원:
          • Brittany K. Ragon
      • Winston-Salem, North Carolina, 미국, 27157
        • 모병
        • Wake Forest University Health Sciences
        • 수석 연구원:
          • Rupali R. Bhave
        • 연락하다:
          • Site Public Contact
          • 전화번호: 336-713-6771
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Andrew Srisuwananukorn
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma Health Sciences Center
        • 연락하다:
        • 수석 연구원:
          • Zimu Gong
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health and Science University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 503-494-1080
          • 이메일: trials@ohsu.edu
        • 수석 연구원:
          • Jessica M. Stempel
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University/Ingram Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-811-8480
        • 수석 연구원:
          • Ashwin Kishtagari
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • 모병
        • Huntsman Cancer Institute/University of Utah
        • 연락하다:
        • 수석 연구원:
          • Ami Patel
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • 모병
        • VCU Massey Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Thuy Ho

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must have morphologically confirmed diagnosis of Philadelphia-chromosome negative MPN in accelerated-phase (10-19% myeloid blasts) or blast-phase (≥ 20% myeloid blasts) arising from polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, or MPN not otherwise specified, as per the World Health Organization (WHO) 2016 classification OR myelodysplastic syndrome (MDS)/MPN overlap syndromes (e.g., chronic myelomonocytic leukemia [CMML]) with ≥ 10% blasts

  • Patients must not have received prior DNMTi. Previous use of janus kinase (JAK) inhibition, hydroxyurea, and interferon is allowed. There is no required washout period for JAK inhibition and interferon

  • Age ≥ 18 years

    • Because no dosing or adverse event data are currently available on the use of ASTX727 (35 mg decitabine + 100 mg cedazuridine) in combination with iadademstat in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 (Karnofsky ≥ 30)

  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (unless elevated due to Gilbert's syndrome, thought to be related to MPN-AP/BP, or due to extrasvascular hemolysis. In these cases conjugated bilirubin should be ≤ 2.0 x ULN)

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN

  • Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 by Modification of Diet in Renal Disease (MDRD)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better

  • The effects of ASTX727 (35 mg decitabine + 100 mg cedazuridine) and/or iadademstat on the developing human fetus are unknown. For this reason and because DNMT inhibitor and LSD1 inhibitor agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation and 6 months after completion of ASTX727 (35 mg decitabine + 100 mg cedazuridine) and/or iadademstat administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation and 6 months after completion of ASTX727 (35 mg decitabine + 100 mg cedazuridine) and/or iadademstat administration

  • Women of child-bearing potential must agree not to donate or freeze egg(s) during the course of this study or within 180 days after receiving their last dose of study drug. Male patients must agree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug

  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

  • Patient is able to swallow oral medications

  • Patients must have a body weight of at least 50 kg due to the use of flat doses. If a patient is on continued treatment and is receiving benefit, but falls below 50 kg, they may stay on the study per investigator discretion. Otherwise, they will have to come off the study

  • Peripheral white blood cell (WBC) count < 25 x 10^9/L on day 1 prior to treatment initiation. Hydroxyurea is allowed for cytoreduction until 24 hours prior to study treatment. Hydroxyurea may be resumed during cycle 1 if WBC count rises above 25 x 10^9/L. Use of hydroxyurea beyond cycle 1 should be discussed with study chair

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
  • Patients who are receiving any other investigational agents or had received any investigational products within 3 weeks or 5 half-lives (whichever is shorter) prior to first dose of study treatment
  • Patients with a Fridericia's corrected QT interval (QTcF) > 450 ms
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727 (35 mg decitabine + 100 mg cedazuridine) or iadademstat
  • Patients medicated with anti-depressants reported to have KDM1A/LSD1 inhibitory activity: tranylcypromine or phenelzine
  • Patients with IDH1-mutated MPN blast phase (≥ 20% blasts). Patients with an IDH1-mutation with MPN-AP (10-19%) blasts are eligible for this study
  • Iadademstat concomitant medication considerations: Patients are not allowed to receive prophylactic hematopoietic colony stimulating factors, any complementary or alternative medicine [any of various systems of healing or treating disease (as non-prescription supplements, herbal medicine and homeopathy)]. Of note, patients may receive granulocyte colony-stimulating factor for management of febrile neutropenia or for prolonged neutropenia
  • Patients may not receive administration of live or live-attenuated vaccines. Administration of non-live vaccines included ribonucleic acid (RNA)-based vaccines is allowed and is recommended for pneumococcal, coronavirus, and influenza vaccines
  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
  • Pregnant women are excluded from this study because iadademstat is an LSD1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with iadademstat, breastfeeding should be discontinued if the mother is treated with iadademstat. These potential risks also apply to the ASTX727 (35 mg decitabine + 100 mg cedazuridine) used in this study
  • Patients who require treatment while on study with concomitant drugs that target the 5HT2B receptor or the sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline) except for drugs that are considered absolutely essential for the care of the patient and with appropriate treatment monitoring

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I (ASTX727)

Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given PO

다른 이름들:
  • ASTX727
  • CDA 억제제 E7727/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 정제
  • 인코비
  • C-DEC
  • 12-C
  • ASTX 727
  • ASTX-727
  • 이나코비

Undergo buccal swab and blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집
실험적: Arm II (ASTX727, iadademstat)

Patients receive ASTX727 PO QD on days 1-5 and iadademstat PO QD on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given PO

다른 이름들:
  • ASTX727
  • CDA 억제제 E7727/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 정제
  • 인코비
  • C-DEC
  • 12-C
  • ASTX 727
  • ASTX-727
  • 이나코비

Undergo buccal swab and blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Given PO

다른 이름들:
  • 오리 1001
  • ORY-1001
  • RG 6016
  • RG6016
  • RO 7051790
  • RO7051790
  • trans-N1-((1R,2S)-2-페닐사이클로프로필)-1,4-사이클로헥산디아민

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Acute leukemia response-complete (ALR-C) rate
기간: Within 4 cycles (cycle length = 28 days)

ALR-C rates will be compared between the two treatment arms using Fisher's exact test at the one-sided, alpha = 0.15 significance level.

Within 4 cycles (cycle length = 28 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Event-free survival
기간: From day 1 of randomization to the date of treatment failure, hematological relapse from ALR-C, or death from any cause up to 2 years

Treatment failure is defined as not achieving ALR-C by four cycles of therapy. Hematological relapse is defined as ≥ 5% blasts in bone marrow or peripheral blood or development of myeloid sarcoma after achievement of ALR-C or better. Kaplan-Meier curves will be generated and the two treatment arms will be compared using a stratified log rank test. Cox regression modeling, including treatment arm and dichotomized blast percentage as covariates, will also be performed to estimate the hazard ratio, along with a 90% confidence interval.

From day 1 of randomization to the date of treatment failure, hematological relapse from ALR-C, or death from any cause up to 2 years
Overall survival (OS)
기간: From randomization to the time of death due to any cause up to 2 years

Kaplan-Meier curves will be generated, and the two treatment arms will be compared using a stratified log rank test. Cox regression modeling including treatment arm and dichotomized blast percentage as covariates, will also be performed to estimate the hazard ratio, along with a 90% confidence interval.

From randomization to the time of death due to any cause up to 2 years
Percentage of allogeneic hematopoietic stem cell transplantation (allo-HCT)
기간: Up to 2 years

Descriptive statistics will be utilized for analysis and will be broken down by which treatment arm to which a patient is assigned. The number receiving allo-HCT will be compared between the two treatment arms using Fisher's exact test.

Up to 2 years

기타 결과 측정

결과 측정
측정값 설명
기간
Gene expression levels
기간: After one cycle of therapy (cycle length = 28 days)

Will be compared between the two treatment groups using two-sample t-tests following log2 transformation.

After one cycle of therapy (cycle length = 28 days)
Transcriptional changes in proliferative pathways and molecular pathways associated with resistance/disease progression
기간: Up to 2 years

Will be summarized descriptively.

Up to 2 years
Correspondence between responses
기간: Up to 2 years

Correspondence between responses as determined by the European LeukemiaNet 2022 acute myeloid leukemia criteria versus the 2012 blast phase myeloproliferative neoplasm criteria will be assessed using McNemar's test.

Up to 2 years
Incidence of adverse events (AEs)
기간: Up to 30 days after last dose of study treatment

AEs will be described and graded using National Cancer Institute Common Terminology Criteria for Adverse Events. AEs will be summarized by type, severity grade, and attribution to treatment. Comparisons between treatment arms will be performed using Fisher's exact test.

Up to 30 days after last dose of study treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Anand A Patel, City of Hope Comprehensive Cancer Center LAO

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 8월 14일

기본 완료 (추정된)

2027년 12월 31일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2024년 10월 25일

QC 기준을 충족하는 최초 제출

2024년 10월 25일

처음 게시됨 (실제)

2024년 10월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 24일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다